The interpretation of logophoric and ordinary pronouns in Ewe: an experimental study
Proceedings of the Amsterdam Colloquium · 01.12.2024 · 344-350
DOI: 10.53437/bj43x181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the Amsterdam Colloquium, online erschienen am 01.12.2024. Verfasst von Silvia Silleresi und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study examines the interpretation of logophoric and ordinary pronouns in Ewe. While the logophor yè is predicted to obligatorily refer to the attitude holder in indirect speech reports, the ordinary pronoun’s reference pattern remains debated. Thirty-eight Ewe speaking adults completed an acceptability judgment task evaluating pronoun usage in self and anti-self contexts for communicative (say) and mental (think) verbs. The findings align with the principle of Maximize Presupposition, assuming yè encodes a presupposition: yè is preferred when its presupposition is met, blocking the occurrence of the ordinary pronoun é. In turn, é is favored only where the presupposition of yè fails, though less robustly than yè.
Zitieren
APA
Silleresi, S., Bassi, I., Bimpeh, A. A., Driemel, I., Nuworsu, A., & Guasti, M. T. (2024). The interpretation of logophoric and ordinary pronouns in Ewe: an experimental study. Proceedings of the Amsterdam Colloquium, 344-350. https://doi.org/10.53437/bj43x181
Vancouver
Silleresi S, Bassi I, Bimpeh AA, Driemel I, Nuworsu A, Guasti MT. The interpretation of logophoric and ordinary pronouns in Ewe: an experimental study. Proceedings of the Amsterdam Colloquium. 2024:344-350. doi:10.53437/bj43x181
BibTeX
@article{Silleresi2024,
author = {Silleresi, Silvia and Bassi, Itai and Bimpeh, Abigail Anne and Driemel, Imke and Nuworsu, Anastasia and Guasti, Maria Teresa},
title = {The interpretation of logophoric and ordinary pronouns in Ewe: an experimental study},
journal = {Proceedings of the Amsterdam Colloquium},
year = {2024},
pages = {344--350},
doi = {10.53437/bj43x181}
}
EUVIMED